Please login to the form below

Not currently logged in
Email:
Password:

Imbruvica

This page shows the latest Imbruvica news and features for those working in and with pharma, biotech and healthcare.

BeiGene gets speedy US review for lymphoma drug zanubrutinib

BeiGene gets speedy US review for lymphoma drug zanubrutinib

BeiGene is trying to position zanubrutinib as a rival to AbbVie/Johnson &Johnson’s well-established BTK inhibitor Imbruvica (ibrutinib), which is already approved for several haematological disorders – including CLL, MCL ... Calquence made $64m in

Latest news

  • Imbruvica gains expanded use in Europe Imbruvica gains expanded use in Europe

    Rival Calquence receives accelerated review in US. AbbVie and Janssen’s Imbruvica (ibrutinib) has received approval from the European Commission (EC) for two expanded variations to broaden the use of the ... Imbruvica has experienced some heated

  • AbbVie to acquire Allergan for $63bn AbbVie to acquire Allergan for $63bn

    Analysts have not been overly impressed with the bolt-on acquisitions AbbVie has paid for in recent years; the $21bn it spent acquiring Pharmacyclics and its lymphoma treatment Imbruvica was seen

  • AZ’s Calquence threatens Imbruvica with new leukaemia data AZ’s Calquence threatens Imbruvica with new leukaemia data

    in its market battle with AbbVie/Johnson &Johnson’s Imbruvica. ... That could give Calquence a leg-up as it tries to make inroads against Imbruvica (ibrutinib), which is already approved as a first- and second-line therapy for CLL and a

  • MorphoSys eyes 2020 launch for lymphoma CAR-T challenger MorphoSys eyes 2020 launch for lymphoma CAR-T challenger

    lymphocytic lymphoma (SLL) who have failed or become intolerant to prior treatment with Johnson &Johnson’s Imbruvica (ibrutinib).

  • Venclexta plus Gazyva approval adds to non-chemo options in CLL Venclexta plus Gazyva approval adds to non-chemo options in CLL

    Roche’s marketing partner AbbVie has a stake in a direct rival, Imbruvica, which it co-markets with J&J. ... In January, Imbruvica gained approval in first line treatment in combination with Gazyva, making it the first non-chemo combination in this

More from news
Approximately 30 fully matching, plus 63 partially matching documents found.

Latest Intelligence

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    The firm also has what it hopes is a best- in-class BTK inhibitor, zanubrutinib, in phase III trials, which it believes can be shown superior to Janssen’s Imbruvica. ... Further down the line, Oyler also suggests the drug could emerge as the winner in

  • Biopharma's Future: Made in China Biopharma's Future: Made in China

    It has just submitted its PD-1 immunotherapy candidate tislelizumab with China’s regulator, and also has a late-stage BTK inhibitor to challenge J&J’s Imbruvica with a potential

  • Taking a strategic approach Taking a strategic approach

    In the case of blood cancer drug Imbruvica (ibrutinib) - a key new product for the company - Janssen has requested its single technology appraisal for CLL and MCL be rescheduled to start

  • Pharma deals in March 2015 Pharma deals in March 2015

    Imbruvica is co-commercialised by J&J with Pharmacyclics on a global profit share arrangement under a deal agreed in December 2011. ... At that time Imbruvica was in phase 2 and J&J paid $150m upfront and up to $825m in milestones.

  • Pharma deals during November 2014 Pharma deals during November 2014

    AZ has been busy this month and in the deal with J&J, AZ will match its closely-watched PD-L1 checkpoint inhibitor MEDI4736 with Imbruvica.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics